2024 AACR Presentation:
Early Detection of Renal Cell Carcinoma
Mapping Human Immunity
Mapping Human Immunity
Serimmune is an immune intelligence company that decodes the breadth and complexity of human antibody response, empowering discovery projects through a universal serology assay that identifies disease-specific epitopes across proteins and entire proteomes.
Introducing Immune Profiling Services
SERA Platform Used to Identify Features of Long COVID
Serimmune Announces Use of Its SERA Platform in Study
Serimmune’s proprietary Serum Epitope Repertoire Analysis (SERA) technology platform was one of the methods used to analyze the biological processes associated with the development and persistence of Long COVID symptoms, such as fatigue, brain fog and malaise.
Broad Serosurveillance Using SERA Technology
Broad Serosurveillance Using SERA Technology
View our webinar walking through the use of SERA in Broad Serosurveillance and its use as a tool for research applications.
What We Do
We offer a discovery service to academia, government and industry through the Serimmune universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly profile antibody repertoires and identify antigens and epitopes associated with many diseases - all in a single assay.
How We Do It
Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next-generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Through this, we gain a broad view of an individual’s environmental exposures and the unique immune responses to these exposures in disease and health.
Why We Do It
Serimmune was founded on the belief that the information coded in the individual’s functional antibody repertoire is key to understanding human disease. To fulfill this vision, we created a technology for building and interpreting a dynamic map of human immunity which continually evolves to map interactions between functional antibody repertoire and human disease. Linkages between antibody response to pathogens have been shown in oncology, autoimmune, infectious, neurodegenerative, and other complex diseases.
Immuno-Therapeutics
Vaccines
Target Discovery
Serimmune Biomarker Discovery Service
Learn about Serimmune’s SERA platform which combines large biological libraries, NGS, and custom bioinformatics to unlock the Circulating Antibody Repertoire to achieve hypothesis free serology.
Neutralizing Epitopes
Biomarkers of Response
Events
From basic research to commercial manufacture, this one meeting covers the whole vaccine value chain where science, government and manufacturers all come together to create groundbreaking progress.
Join us at Booth 630!
World Vaccine Congress
April 1st-4th
Washington, D.C.
AACR Annual Meeting
April 5th-10th
San Diego, CA
Serimmune Presentation
April 7, 2024, 1:30 PM - 5:00 PM
Session PO.CL01.15 – Early Detection Biomarkers 1
1056 / 4 – Development of a B-cell epitope classifier for early detection of renal cell carcinoma
Workshops on Recent Issues in Bioanalysis hosts 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies to discuss current topics of interest.
WRIB
May 6th-10th
San Antonio, TX
In the News
Frontiers in Immunology